Can Isoray Inc (de (NYSEAMERICAN:ISR)’s Tomorrow Be Different? The Stock Had Decline in Shorts

IsoRay, Inc. (NYSEAMERICAN:ISR) Logo

Investors sentiment decreased to 1 in 2019 Q2. Its down 0.40, from 1.4 in 2019Q1. It dived, as 3 investors sold IsoRay, Inc. shares while 3 reduced holdings. 4 funds opened positions while 2 raised stakes. 3.67 million shares or 20.14% less from 4.60 million shares in 2019Q1 were reported.
Jnba Advisors stated it has 0% of its portfolio in IsoRay, Inc. (NYSEAMERICAN:ISR). California Employees Retirement Systems invested in 0% or 117,100 shares. Royal Commercial Bank Of Canada stated it has 21,000 shares or 0% of all its holdings. Crestwood Advsrs Grp Incorporated Llc has invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Northern Trust Corp has 0% invested in IsoRay, Inc. (NYSEAMERICAN:ISR) for 124,577 shares. The Texas-based Utd Service Automobile Association has invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Morgan Stanley accumulated 1,473 shares or 0% of the stock. Vanguard Gru has invested 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Two Sigma Secs Ltd, New York-based fund reported 60,130 shares. Citadel Advsr Llc owns 39,007 shares for 0% of their portfolio. Auxier Asset Management stated it has 0% of its portfolio in IsoRay, Inc. (NYSEAMERICAN:ISR). 15,768 were accumulated by Susquehanna Group Ltd Liability Partnership. Sabby Management Limited Liability Com owns 370,612 shares. Savings Bank Of America De stated it has 0% in IsoRay, Inc. (NYSEAMERICAN:ISR). Ifrah Finance Services Incorporated stated it has 30,000 shares or 0% of all its holdings.

The stock of Isoray Inc (de (NYSEAMERICAN:ISR) registered a decrease of 15.47% in short interest. ISR’s total short interest was 588,600 shares in September as published by FINRA. Its down 15.47% from 696,300 shares, reported previously. With 144,200 shares average volume, it will take short sellers 4 days to cover their ISR’s short positions.

The stock decreased 0.41% or $0.0013 during the last trading session, reaching $0.312. About 33,289 shares traded. IsoRay, Inc. (NYSEAMERICAN:ISR) has declined 43.44% since September 13, 2018 and is downtrending. It has underperformed by 43.44% the S&P500.

IsoRay, Inc. develops, manufactures, and sells isotope medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company has market cap of $21.01 million. The firm produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It currently has negative earnings. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.

More notable recent IsoRay, Inc. (NYSEAMERICAN:ISR) news were published by: Globenewswire.com which released: “Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting – GlobeNewswire” on June 12, 2019, also Finance.Yahoo.com with their article: “Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting – Yahoo Finance” published on September 10, 2019, Finance.Yahoo.com published: “UEC Comments on the Presidential Memoranda Issued on Uranium and Establishment of the U.S. Nuclear Fuel Working Group – Yahoo Finance” on July 15, 2019. More interesting news about IsoRay, Inc. (NYSEAMERICAN:ISR) were released by: Globenewswire.com and their article: “Isoray Announces Record Third Quarter Fiscal 2019 Financial Results – GlobeNewswire” published on May 09, 2019 as well as Globenewswire.com‘s news article titled: “IsoRay Announces the Appointment of Lori Woods As Chief Executive Officer – GlobeNewswire” with publication date: December 17, 2018.

IsoRay, Inc. (NYSEAMERICAN:ISR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.